Role of Direct Antiviral Agents in Treatment of Chronic Hepatitis C Infection in Renal Transplant Recipients

Background. Since the introduction of direct antiviral agents (DAAs), morbidity of HCV has considerably decreased but still no guidelines have been formulated in renal transplant recipients (RTRs). We studied efficacy and tolerability of direct antiviral agents in RTRs. Methods. This prospective obs...

Full description

Bibliographic Details
Main Authors: Sourabh Sharma, Debabrata Mukherjee, Ranjith K. Nair, Bhaskar Datt, Ananth Rao
Format: Article
Language:English
Published: Hindawi Limited 2018-01-01
Series:Journal of Transplantation
Online Access:http://dx.doi.org/10.1155/2018/7579689
id doaj-881441cd70b1417aa2b888bfe508614e
record_format Article
spelling doaj-881441cd70b1417aa2b888bfe508614e2020-11-24T20:54:59ZengHindawi LimitedJournal of Transplantation2090-00072090-00152018-01-01201810.1155/2018/75796897579689Role of Direct Antiviral Agents in Treatment of Chronic Hepatitis C Infection in Renal Transplant RecipientsSourabh Sharma0Debabrata Mukherjee1Ranjith K. Nair2Bhaskar Datt3Ananth Rao4Army Hospital Research & Referral, Delhi, IndiaArmy Hospital Research & Referral, Delhi, IndiaArmy Hospital Research & Referral, Delhi, IndiaArmy Hospital Research & Referral, Delhi, IndiaArmy Hospital Research & Referral, Delhi, IndiaBackground. Since the introduction of direct antiviral agents (DAAs), morbidity of HCV has considerably decreased but still no guidelines have been formulated in renal transplant recipients (RTRs). We studied efficacy and tolerability of direct antiviral agents in RTRs. Methods. This prospective observational study was conducted at Army Hospital Research & Referral, Delhi, from June 2016 to May 2017. Forty-five HCV infected RTRs with stable graft function were included. Results. Median time between renal transplantation and the start of anti-HCV therapy was 36 months (1–120 months). The majority (66.7%) were infected with genotype 3. Baseline median HCV RNA level was 542648 IU/ml (1189–55028534 IU/ml). Sofosbuvir-Ribavirin combination (24 weeks) was given to 30 patients including 3 cirrhotics, Ledipasvir-Sofosbuvir combination to 8 patients, and Daclatasvir-Sofosbuvir combination to 7 patients, including 2 cirrhotics. Rapid virological response was observed in 29 patients treated with Sofosbuvir/Ribavirin, all 8 patients on Sofosbuvir/Ledipasvir, and all 7 patients on Sofosbuvir/Daclatasvir. End treatment response and sustained virological response (12 weeks) were achieved in all patients irrespective of genotype or treatment regimen. Decrease in mean HCV RNA level and transaminase level was statistically significant (p<0.01). Ribavirin was significantly associated with anaemia (p=0.032). Conclusions. DAA regimens are well tolerated and highly efficacious. Response to DAA is good irrespective of genotype, drug combination, initial HCV RNA level, age or sex of patient, or graft age. However, Sofosbuvir/Ledipasvir and Sofosbuvir/Daclatasvir combination is preferable.http://dx.doi.org/10.1155/2018/7579689
collection DOAJ
language English
format Article
sources DOAJ
author Sourabh Sharma
Debabrata Mukherjee
Ranjith K. Nair
Bhaskar Datt
Ananth Rao
spellingShingle Sourabh Sharma
Debabrata Mukherjee
Ranjith K. Nair
Bhaskar Datt
Ananth Rao
Role of Direct Antiviral Agents in Treatment of Chronic Hepatitis C Infection in Renal Transplant Recipients
Journal of Transplantation
author_facet Sourabh Sharma
Debabrata Mukherjee
Ranjith K. Nair
Bhaskar Datt
Ananth Rao
author_sort Sourabh Sharma
title Role of Direct Antiviral Agents in Treatment of Chronic Hepatitis C Infection in Renal Transplant Recipients
title_short Role of Direct Antiviral Agents in Treatment of Chronic Hepatitis C Infection in Renal Transplant Recipients
title_full Role of Direct Antiviral Agents in Treatment of Chronic Hepatitis C Infection in Renal Transplant Recipients
title_fullStr Role of Direct Antiviral Agents in Treatment of Chronic Hepatitis C Infection in Renal Transplant Recipients
title_full_unstemmed Role of Direct Antiviral Agents in Treatment of Chronic Hepatitis C Infection in Renal Transplant Recipients
title_sort role of direct antiviral agents in treatment of chronic hepatitis c infection in renal transplant recipients
publisher Hindawi Limited
series Journal of Transplantation
issn 2090-0007
2090-0015
publishDate 2018-01-01
description Background. Since the introduction of direct antiviral agents (DAAs), morbidity of HCV has considerably decreased but still no guidelines have been formulated in renal transplant recipients (RTRs). We studied efficacy and tolerability of direct antiviral agents in RTRs. Methods. This prospective observational study was conducted at Army Hospital Research & Referral, Delhi, from June 2016 to May 2017. Forty-five HCV infected RTRs with stable graft function were included. Results. Median time between renal transplantation and the start of anti-HCV therapy was 36 months (1–120 months). The majority (66.7%) were infected with genotype 3. Baseline median HCV RNA level was 542648 IU/ml (1189–55028534 IU/ml). Sofosbuvir-Ribavirin combination (24 weeks) was given to 30 patients including 3 cirrhotics, Ledipasvir-Sofosbuvir combination to 8 patients, and Daclatasvir-Sofosbuvir combination to 7 patients, including 2 cirrhotics. Rapid virological response was observed in 29 patients treated with Sofosbuvir/Ribavirin, all 8 patients on Sofosbuvir/Ledipasvir, and all 7 patients on Sofosbuvir/Daclatasvir. End treatment response and sustained virological response (12 weeks) were achieved in all patients irrespective of genotype or treatment regimen. Decrease in mean HCV RNA level and transaminase level was statistically significant (p<0.01). Ribavirin was significantly associated with anaemia (p=0.032). Conclusions. DAA regimens are well tolerated and highly efficacious. Response to DAA is good irrespective of genotype, drug combination, initial HCV RNA level, age or sex of patient, or graft age. However, Sofosbuvir/Ledipasvir and Sofosbuvir/Daclatasvir combination is preferable.
url http://dx.doi.org/10.1155/2018/7579689
work_keys_str_mv AT sourabhsharma roleofdirectantiviralagentsintreatmentofchronichepatitiscinfectioninrenaltransplantrecipients
AT debabratamukherjee roleofdirectantiviralagentsintreatmentofchronichepatitiscinfectioninrenaltransplantrecipients
AT ranjithknair roleofdirectantiviralagentsintreatmentofchronichepatitiscinfectioninrenaltransplantrecipients
AT bhaskardatt roleofdirectantiviralagentsintreatmentofchronichepatitiscinfectioninrenaltransplantrecipients
AT ananthrao roleofdirectantiviralagentsintreatmentofchronichepatitiscinfectioninrenaltransplantrecipients
_version_ 1716793067451711488